Canadian Regulators Ease Post-Treatment Restrictions for BREYANZI CAR T Cell Therapy

Health authorities in Canada have updated guidelines for BREYANZI CAR T cell therapy, shortening the required proximity to a specialized treatment center post-infusion. This change from 28 to 14 days offers patients more flexibility in their follow-up care and could help alleviate pressure on healthcare facilities.